Target Price | $61.32 |
Price | $38.76 |
Potential |
58.20%
register free of charge
|
Number of Estimates | 22 |
22 Analysts have issued a price target Ionis Pharmaceuticals, Inc. 2025 .
The average Ionis Pharmaceuticals, Inc. target price is $61.32.
This is
58.20%
register free of charge
$82.00
111.56%
register free of charge
$37.00
4.54%
register free of charge
|
|
A rating was issued by 27 analysts: 19 Analysts recommend Ionis Pharmaceuticals, Inc. to buy, 7 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Ionis Pharmaceuticals, Inc. stock has an average upside potential 2025 of
58.20%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 787.65 | 621.46 |
34.10% | 21.10% | |
EBITDA Margin | -42.05% | -84.40% |
36.35% | 100.70% | |
Net Margin | -47.46% | -84.33% |
0.48% | 77.68% |
22 Analysts have issued a sales forecast Ionis Pharmaceuticals, Inc. 2024 . The average Ionis Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Ionis Pharmaceuticals, Inc. EBITDA forecast 2024. The average Ionis Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
23 Ionis Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average Ionis Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.56 | -3.59 |
34.74% | 40.23% | |
P/E | negative | |
EV/Sales | 9.67 |
23 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast for earnings per share. The average Ionis Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Ionis Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Ionis Pharmaceuticals, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.